Abstract
Treatment of infected patients with ABT-538, an inhibitor of the protease of human immunodeficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease exponentially (mean half-life, 2.1 +/- 0.4 days) and CD4 lymphocyte counts to rise substantially. Minimum estimates of HIV-1 production and clearance and of CD4 lymphocyte turnover indicate that replication of HIV-1 in vivo is continuous and highly productive, driving the rapid turnover of CD4 lymphocytes.
Publication types
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
MeSH terms
- Antiviral Agents / therapeutic use
- CD4 Lymphocyte Count / drug effects
- CD4-Positive T-Lymphocytes / cytology
- CD4-Positive T-Lymphocytes / virology*
- HIV Infections / drug therapy
- HIV Infections / immunology
- HIV Infections / virology*
- HIV Protease Inhibitors / therapeutic use
- HIV-1 / physiology*
- Humans
- Kinetics
- Ritonavir
- Viremia / drug therapy
- Viremia / virology*
- Virion / physiology
- Virus Replication*
Substances
- Antiviral Agents
- HIV Protease Inhibitors
- Ritonavir